• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Drugs of Today

    Drugs of Today

    JournalISSN 1699-3993eISSN 1699-4019中科院 医学 4区

    年发文量

    研究主题

    论文(2413)

    排序
    1Anakinra As a Potential Treatment for COVID-19.
    Matthew W McCarthy

    On November 8, 2022, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the interleukin-1 (IL-1) inhibitor anakinra for the treatment of patients with COVID-19 pneumonia. The authorization was specifically intended for patients requiring supplemental oxygen who are at risk of progression to respiratory failure and are likely to have an elevated plasma soluble urokinase plasminogen activator receptor. Anakinra is a modified, recombinant human IL-1 receptor antagonist used to treat rheumatoid arthritis, neonatal-onset multisystem inflammatory disease and other inflammatory diseases. This manuscript examines what is known about the role of IL-1 receptor antagonism in the treatment of patients with COVID-19 and examines how anakinra may be used in the future to address the SARS-CoV-2 infection pandemic.

    2023引用:1
    引用
    AI阅读
    加入学术空间
    2Savolitinib for Non-Small Cell Lung Cancer
    Magdalena Zaborowska-Szmit,Sebastian Szmit,Maciej Krzakowski,Dariusz M. Kowalski

    Savolitinib is a highly selective MET tyrosine kinase inhibitor. MET is involved in numerous cellular processes such as proliferation, differentiation and the formation of distant metastases. MET amplification and MET overexpression are quite common in many cancers, but MET exon 14 skipping alteration is most common in non-small cell lung cancer (NSCLC). The role of MET signaling as a bypass pathway in the development of acquired resistance to tyrosine kinase inhibitor (TKI) epidermal growth factor receptor (EGFR) therapy in cancer patients with EGFR gene mutation was documented. Potential beneficiaries of savolitinib therapy are patients with NSCLC and initial diagnosis of MET ex 14 skipping mutation. Savolitinib therapy can be effective in NSCLC patients with EGFR-mutant MET with progression during first-line treatment with an EGFR-TKI. Antitumor activity of savolitinib in combination with osimertinib is very promising as first-line therapy of patients with advanced EGFR-mutated NSCLC, initially with MET expression. The safety profile of savolitinib as monotherapy and in combination with osimertinib or gefitinib is so favorable in all available studies that this drug has become a very promising therapeutic option and is being intensively investigated in ongoing clinical trials.

    2023引用:5
    引用
    AI阅读
    加入学术空间
    3Lutetium Lu 177 Vipivotide Tetraxetan for Prostate Cancer
    Xing Liu,Gao-Chuan Fang, Hao Lu,Zhen-Duo Shi,Zhe-Sheng Chen,Cong-Hui Han

    On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have highly expressed prostate-specific membrane antigen (PSMA) and have at least one metastatic lesion. It is the first FDA-approved targeted radioligand therapy for eligible men with PSMA-positive mCRPC. Lutetium Lu 177 vipivotide tetraxetan is a radioligand that strongly binds to PSMA, making it ideal for treating cancers of the prostate by targeted radiation, resulting in DNA damage and cell death. PSMA is overexpressed in cancer cells while being lowly expressed in normal tissues, which makes it an ideal theranostic target. As precision medicine advances, this is a thrilling turning point for highly individualized treatments. This review aims to summarize the pharmacology and clinical studies of the novel drug lutetium Lu 177 vipivotide tetraxetan for the treatment of mCRPC, emphasizing its mechanism of action, pharmacokinetics and safety.

    2023引用:8
    引用
    AI阅读
    加入学术空间
    4Nivolumab and Relatlimab for the Treatment of Melanoma
    Xuan-Yu Chen,Yi-Dong Li,Yuhao Xie,Lu-Qi Cao,Charles R. Ashby,Hongbing Zhao,Zhe-Sheng Chen

    Melanoma is a highly lethal type of skin cancer. Although an early diagnosis, in combination with surgery for nonmetastatic melanomas, significantly increases the probability of survival, there are no efficacious treatments for metastatic melanoma. Nivolumab and relatlimab are monoclonal antibodies that selectively interact with and block the proteins programmed cell death protein 1 (PD-1) and lymphocyte activation protein 3 (LAG-3), respectively, and thus, their activation by their cognate ligands. The combination of these immunotherapy drugs was approved in 2022 by the United States Food and Drug Administration (FDA) for the treatment of melanoma. Data from clinical trials indicated that, compared to nivolumab monotherapy, nivolumab and relatlimab produced more than a 2-fold median increase in progression-free survival (PFS) and a higher response rate in melanoma patients. This is an important finding as the response of patients to immunotherapies is limited due to dose-limiting toxicities and secondary drug resistance. This review article will discuss the pathogenesis of melanoma and the pharmacology of nivolumab and relatlimab. In addition, we will provide i) a summary of the anticancer drugs that inhibit LAG-3 and PD-1 in cancer patients and ii) our perspective about the use of nivolumab in combination with relatlimab to treat melanoma.

    2023引用:6
    引用
    AI阅读
    加入学术空间
    5Anifrolumab in Systemic Lupus Erythematosus
    Michael F. Loncharich,Ian Robertson

    Systemic lupus erythematosus is a complex autoimmune disease with variable disease presentation and progression. Hydroxychloroquine and corticosteroids are first-line therapies. Disease severity and organ system involvement guide escalation of immunomodulatory medications beyond these mainstays. Anifrolumab is a first-in-class global type 1 interferon inhibitor recently approved by the United States Food and Drug Administration (FDA) for systemic lupus erythematosus in addition to standard of care. This article reviews the role of type 1 interferons in lupus pathophysiology and the evidence leading to anifrolumab's approval with particular emphasis on the MUSE, TULIP-1 and TULIP-2 trials. In addition to standard of care, anifrolumab can reduce corticosteroid requirements and reduce lupus disease activity, especially skin and musculoskeletal manifestations, with an acceptable safety profile.

    2023引用:9
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 2413 篇论文

    高被引作者

    作者引用发文
    Antonio Jimeno104339
    Xavier Rabasseda83490
    Stephen Durham4781
    A S Peña46723
    Ba Cunha43512
    D M Paton31829
    Owen Richard T31316
    Servaas A. Morré2979
    P Rutgeerts29712
    Hedges Dawson W2912

    高产作者

    作者引用发文
    Xavier Rabasseda83490
    Antonio Jimeno104339
    Gras J18739
    D M Paton31829
    Zelalem Temesgen28527
    A S Peña46723
    A. I. Graul23423
    Owen Richard T31316
    Arunava Dasgupta16515
    Sidharth Chopra16515

    相关期刊

    Clinical pharmacokinetics
    Drugs in R&D
    Expert opinion on investigational drugs
    Academic Pathology
    Expert opinion on biological therapy
    Clinical Pharmacology In Drug Development(Electronic)
    Journal Of Clinical Pharmacology
    Drugs of the Future
    Expert Opinion on Emerging Drugs
    International Journal of Clinical Pharmacology and Therapeutics